Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.64 |
| ▸ | MAOA | P21397 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832684 | 1.00 | CALML3 (0.64) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL8111357 | 1.00 | CALML3 (0.64) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL4013373 | 0.89 | MAOB (0.50) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL14574048 | 0.88 | MAOB (0.48) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL14302608 | 0.88 | MAOB (0.48) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7857435 | 0.87 | CALML3 (0.50) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL7857432 | 0.87 | CALML3 (0.50) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL14564164 | 0.87 | MAOB (0.48) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL14183166 | 0.87 | MAOB (0.48) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL7840027 | 0.85 | CALML3 (0.60) | CALML3MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | CALML3 4622/4885MAOA 1654/4885MAOB 1178/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | CALML3 4410/4885MAOA 652/4885MAOB 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.